Breast Cancer

Panelists discuss how pharmacists should monitor neutropenia, diarrhea, and mucositis from sacituzumab govitecan (SG); interstitial lung disease (ILD) and neutropenia from trastuzumab deruxtecan (T-DXd); and neutropenia and ILD from datopotamab deruxtecan (Dato-DXd). Proactive management is essential for patient safety.

The findings provide a deeper understanding of the mechanisms underlying breast cancer progression and treatment resistance.

Panelists discuss how antibody-drug conjugates (ADCs) often cause toxic adverse events (AEs). Supportive care includes antiemetics, corticosteroids, and growth factors. Infusion reactions are managed with premedication and slow titration.

Panelists discuss how antibody-drug conjugates (ADCs) often show more diverse outcomes in real-world settings compared with clinical trials, with varying efficacy and adverse effect profiles. Key practical considerations for pharmacists include appropriate dosing based on patient factors, managing drug interactions, implementing premedication protocols to minimize adverse reactions, and providing comprehensive supportive care. Careful monitoring and individualized patient management are essential for optimal therapeutic outcomes.

Panelists discuss how patient characteristics significantly impact antibody-drug conjugate (ADC) therapy selection, with key factors including the presence and location of brain metastases (due to blood-brain barrier penetration), organ function and comorbidities affecting toxicity risks, and prior treatment history that may influence both efficacy and safety. Treatment decisions require careful individualization.

Panelists discuss how emerging antibody-drug conjugates (ADCs) in metastatic breast cancer (mBC) treatment demonstrate innovation through optimized drug-to-antibody ratios, novel payloads, and targeted approaches to different breast cancer subtypes. Key trials explore combinations with established therapies and potential for improved tolerability profiles. Additional notable studies include comparative effectiveness research between approved ADCs and investigation of biomarker-driven patient selection strategies to maximize therapeutic benefit while minimizing adverse effects.

Even when safe, oral supplement use may not be appropriate to use during cancer treatment or recovery.

Panelists discuss how when making antibody-drug conjugate (ADC) treatment decisions for patients with metastatic breast cancer (mBC), pharmacists primarily consider patient-specific factors such as biomarker status, prior therapies, disease burden, and comorbidities. ADCs are typically introduced after standard first-line treatments show inadequacy or in specific molecular subtypes that demonstrate strong responses to targeted therapy.

Panelists discuss how antibody-drug conjugates (ADCs) for breast cancer (BC) differ in their safety profiles, with trastuzumab deruxtecan (T-DXd) having notable interstitial lung disease risk, sacituzumab govitecan (SG) associated with neutropenia/diarrhea, and datopotamab deruxtecan (Dato-DXd) showing a relatively favorable safety profile but still requiring monitoring.

The authors’ findings show a greater decline in those treated with chemotherapy vs endocrine therapy.

New drugs and collaborative care may be key to overcoming trial closures, weak guidelines, and inefficiencies.

Sacituzumab govitecan improves outcomes but requires careful management of adverse effects.

Panelists discuss how HER2 testing optimization requires multisite sampling and quantitative assessment methods to account for intratumoral heterogeneity. Beyond HER2, biomarkers such as PI3K mutations, hormone receptor status, and tumor mutational burden can guide therapy selection for metastatic breast cancer (mBC), enabling more personalized treatment approaches.

Using new treatment advances, traditional medications, genetic profiles, immunotherapies, and individualized plans enables providers to improve outcomes for patients with TPBC.

Black women have higher rates of triple-negative breast cancer (TNBC) incidence and mortality than the general US population. Despite this, they are underrepresented in TNBC clinical trials.

Africa's unparalleled genetic diversity presents both a challenge and an opportunity to advance precision medicine, with a focus on leveraging pharmacogenetics to improve drug efficacy and reduce adverse reactions.

Catriona Jamieson, MD, PhD, discusses the role of stress-activated base editors like ADAR1p150 and APOBEC enzymes in cancer progression and highlights innovative approaches to halt these processes and improve therapeutic outcomes.

The Trop-2-tagreting antibody drug conjugate facilitated improved intracranial penetration with favorable tolerability.

Topical, targeted drug delivery increases drug concentrations at the desired site while also reducing toxicity and unwanted adverse effects.

Digoxen is the active ingredient found in the foxglove plant and is commonly used to treat heart failure.

Presence of comorbidities in older patients with breast cancer complicates treatment decisions.

Black and Native American patients were about 2 to 3 times more likely to die of cancer compared with White patients, and women younger than 50 years were affected more than male patients.

Experts presented results that may transform treatment and clinical practice strategies.

Hormonal contraceptives did not increase breast cancer risk in patients with BRCA2 mutations.

Brentuximab vedotin is approved for treatment of adult and pediatric with classical Hodgkin lymphoma in combination with chemotherapy.